Trisomy 22 as the sole abnormality is an important marker for the diagnosis of acute myeloid leukemia with inversion 16

Onkologie

Volumn 31, Issue 8-9, 2008, Pages 440-444

  Xu, Wei ^a   Zhou, Hui Fen ^a   Fan, Lei ^a   Qian, Si Xuan ^a   Chen, Li Juan ^a   Qiu, Hai Rong ^a   Zhang, Su Jiang ^a   Li, Jian Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Acute myeloid leukemia; Fluorescence in situ hybridization (FISH); Inversion 16; Trisomy 22

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CENTROMERE; CHROMOSOME 16; CHROMOSOME ABERRATION; CHROMOSOME INVERSION; CHROMOSOME Q BAND; CLINICAL ARTICLE; DISEASE MARKER; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; INTERPHASE; KARYOTYPE; MALE; TELOMERE; TRISOMY;

ADOLESCENT; ADULT; AGED; CHROMOSOMES, HUMAN, PAIR 16; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INVERSION, CHROMOSOME; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TRISOMY; YOUNG ADULT;

EID: 52249097424     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000141917     Document Type: Article

References (25)

1. Le Beau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD: Association of an inversion of chromosome 16 with abnormal marrow eosinophils in acute myelomonocytic leukemia. New Engl J Med 1983;309:630-6.
2. Shigesada K, Van de SB, Liu PP: Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene 2004;23:4297-307.
3. Larson RA, Williams SF, Le Beau MM, Bitter MA, Vardiman JW, Rowley JD: Acute myelomonocytic leukemia with abnormal eosinophils and inv(16) or t(16;16) has a favorable prognosis. Blood 1986;68:1242-9.
4. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD; Cancer and Leukemia Group B (CALGB 8461): Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325-36.
5. Byrd JC, Ruppert AS, Mrózek K, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Stamberg J, Koduru PR, Moore JO, Mayer RJ, Davey FR, Larson RA, Bloomfield CD: Repetitive cycles of highdose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol 2004;22:1087-94.
6. Razzouk BI, Raimondi SC, Srivastava DK, Pritchard M, Behm FG, Tong X, Sandlund JT, Rubnitz JE, Pui CH, Ribeiro RC: Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience. Leukemia 2001;15:1326-30.
7. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fiere D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucemies Aigues Myeoblastiques; Leucemies Aigues Myeoblastiques de l'Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups: Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood 2003;102:462-9.
8. Niemeyer MM, Haak HL, Augustinus E, den Nijsvan Weert JI, Leeksma CH: Trisomy of chromosome 22 in acute myelomonocyic leukaemia. Cancer Genet Cytogenet 1986,20:371-4.
9. Najfeld V, Seremetis S, Troy K, Uehlinger J, Schwartz P, Cuttner J: Trisomy 22-a new abnormality found in acute leukaemia characterized by eosinophilia and monocytoid blasts expressing immature differentiation antigens. Cancer Genet Cytogenet 1986;23:105-14.
10. Grois N, Nowotny H, Tyl E, Krieger O, Kier P, Haas OA: Is trisomy 22 in acute myeloid leukaemia a primary abnormality or only a secondary change associated with inversion 16? Cancer Genet Cytogenet 1989;43:119-29.
11. Wong KF, Kwong YL: Trisomy 22 in acute myeloid leukemia: a marker for myeloid leukemia with monocytic features and cytogenetically cryptic inversion 16. Cancer Genet Cytogenet 1999;109:131-3.
12. Litmanovich D, Zamir-Brill R, Jeison M, Gershoni-Baruch R: Is inversion 16 a prerequisite and is trisomy 22 invariably associated with inversion 16 in AML-M4eo? Cancer Genet Cytogenet 2000;121:106.
13. Shaffer LG, Tommerup N (eds): ISCN 2005: An International System for Human Cytogenetic Nomenclature. Basel, S. Karger, 2005.
14. Mancini M, Cedrone M, Diverio D, Emanuel B, Stul M, Vranckx H, Brama M, De Cuia MR, Nanni M, Fazi F, Mecucci C, Alimena G, Hagemeijer A: Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-up: a study of 23 patients. Leukemia 2000;14:364-8.
15. Speicher MR, Gwyn BS, Ward DC: Karyotyping human chromosomes by combinatorial multi-fluor FISH. Nat Genet 1996;12:368-75.
16. Haferlach T, Winkemann M, Löffler H, Schoch R, Gassmann W, Fonatsch C, Schoch C, Poetsch M, Weber-Matthiesen K, Schlegelberger B: The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grumwald-Giemsa staining and fluorescence in situ hybridization. Blood 1996;87:2459-63.
17. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press, 2001, pp. 82-4.
18. Maseki N, Kaneko Y, Sakurai M: Nonrandom additional chromosome changes in acute nonlymphocytic leukemia with inv(16)(p13q22). Cancer Genet Cytogenet 1987;26:309-15.
19. Langabeer SE, Grimwade D, Walker H, Rogers JR, Burnett AK, Goldstone AH, Linch DC: A study to determine whether trisomy 8, deleted 9q and trisomy 22 are marker of cryptic rearrangements of PML/RARα, AML1/ETO and CBFβ/MYH11 respectively in acute myeloid leukaemia. Br J Haematol 1998;101:338-40.
20. Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PR, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD: Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 2001;19:2482-92.
21. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A: The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998;92:2322-33.
22. McGrattan P, Humphreys MW: The prognostic value of FISH as an adjunct to conventional cytogenetics for the detection of cryptic gene rearrangements on chromosome 16. A retrospective investigation of 13 patients from Northern Ireland diagnosed with M4Eo acute myeloid leukemia. Ulster Med J 2003;72:16-2l.
23. Merchant SH, Haines S, Hall B, Hozier J, Viswanatha DS: Fluorescence in situ hybridization identifies cryptic t(16;16)(p13;q22) masked by del(16) (q22) in a case of AML-M4Eo. J Mol Diagn 2004;6:271-4.
24. Marlton P, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich EJ, Estey E: Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia 1995;9:965-71.
25. Tobal K, Johnson PR, Saunders MJ, Harrison CJ, Liu Yin JA: Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br J Haematol 1995;91:104-8.